ABUS Arbutus Biopharma
- 3.780
- -0.050-1.31%
Arbutus Biopharma News
Arbutus Biopharma | 4: Statement of changes in beneficial ownership of securities-Director MANCHESTER KEITH S
Arbutus Biopharma | 10-Q: Q2 2024 Earnings Report
Arbutus Biopharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Arbutus Biopharma | 8-K: Current report
Arbutus Biopharma | 8-K: Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Arbutus Biopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Morgan Stanley(10.3%),Morgan Stanley Investment Management Inc.(10.1%)
Arbutus Biopharma | 8-K: Current report
Arbutus Biopharma | 8-K: Current report
Arbutus Biopharma | 8-K: Current report
Arbutus Biopharma | 4: Statement of changes in beneficial ownership of securities-Director BURGESS DANIEL D
Arbutus Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Rewolinski Melissa
Arbutus Biopharma | 4: Statement of changes in beneficial ownership of securities-Director MANCHESTER KEITH S
Arbutus Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Meyers James R
Arbutus Biopharma | 4: Statement of changes in beneficial ownership of securities-Director HENRIQUES RICHARD C JR
Arbutus Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Torti Frank
Arbutus Biopharma | 8-K: Current report
Arbutus Biopharma | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Whitefort Capital Master Fund, LP(6.8%),Whitefort Capital GP, LLC(6.8%), etc.
Arbutus Biopharma | SC 13D: Statement of acquisition of beneficial ownership by individuals-Whitefort Capital Master Fund, LP(6.8%),Whitefort Capital GP, LLC(6.8%), etc.
Arbutus Biopharma | 10-Q: Q1 2024 Earnings Report
Arbutus Biopharma | 8-K: Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
Analysis
Price Target
No Data
No Data